BR112015028605A2 - método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central - Google Patents

método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central

Info

Publication number
BR112015028605A2
BR112015028605A2 BR112015028605A BR112015028605A BR112015028605A2 BR 112015028605 A2 BR112015028605 A2 BR 112015028605A2 BR 112015028605 A BR112015028605 A BR 112015028605A BR 112015028605 A BR112015028605 A BR 112015028605A BR 112015028605 A2 BR112015028605 A2 BR 112015028605A2
Authority
BR
Brazil
Prior art keywords
inhibiting
treating
preventing
nervous system
disease
Prior art date
Application number
BR112015028605A
Other languages
English (en)
Other versions
BR112015028605A8 (pt
Inventor
Fairbanks Carolyn
Kozarsky Karen
R Belur Lalitha
Scott Mcivor R
Low Walter
Original Assignee
Univ Minnesota
Regenxbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota, Regenxbio Inc filed Critical Univ Minnesota
Publication of BR112015028605A2 publication Critical patent/BR112015028605A2/pt
Publication of BR112015028605A8 publication Critical patent/BR112015028605A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

resumo “método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central” um método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central, por administração via intratecal, intracerebroventricular ou endovascular de um raav que codifica um produto gênico associado com a doença, por exemplo, um mamífero cujo produto gênico está ausente ou presente em um nível reduzido em relação a um mamífero sem a doença.
BR112015028605A 2013-05-15 2014-05-15 uso de uma composição e uso de um imunossupressor e uma composição BR112015028605A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823757P 2013-05-15 2013-05-15
PCT/US2014/038209 WO2014186579A1 (en) 2013-05-15 2014-05-15 Adeno-associated virus mediated gene transfer to the central nervous system

Publications (2)

Publication Number Publication Date
BR112015028605A2 true BR112015028605A2 (pt) 2017-07-25
BR112015028605A8 BR112015028605A8 (pt) 2019-12-24

Family

ID=51898870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028605A BR112015028605A8 (pt) 2013-05-15 2014-05-15 uso de uma composição e uso de um imunossupressor e uma composição

Country Status (13)

Country Link
US (10) US9827295B2 (pt)
EP (2) EP2996475A4 (pt)
JP (4) JP2016523835A (pt)
KR (3) KR20220119187A (pt)
CN (3) CN115120746A (pt)
AU (3) AU2014265417B2 (pt)
BR (1) BR112015028605A8 (pt)
CA (2) CA2912678C (pt)
HK (2) HK1222093A1 (pt)
MX (2) MX2015015560A (pt)
RU (1) RU2692251C2 (pt)
SG (2) SG11201509419QA (pt)
WO (1) WO2014186579A1 (pt)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507507PA (en) 2013-03-15 2015-10-29 Univ Pennsylvania Compositions and methods for treating mpsi
SG11201509419QA (en) * 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
EP3218484A4 (en) 2014-11-14 2018-05-30 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
RU2749882C2 (ru) 2014-11-14 2021-06-18 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
WO2016115503A1 (en) * 2015-01-16 2016-07-21 Voyager Therapeutics, Inc. Central nervous system targeting polynucleotides
WO2016172155A1 (en) 2015-04-23 2016-10-27 University Of Massachusetts Modulation of aav vector transgene expression
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2016187017A1 (en) * 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
US11027024B2 (en) 2015-05-29 2021-06-08 University Of Iowa Research Foundation Methods of delivery of transgenes for treating brain diseases
US20180236105A1 (en) * 2015-10-23 2018-08-23 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
PL3370705T3 (pl) * 2015-11-05 2022-08-01 The General Hospital Corporation Dooponowe dostarczanie sekwencji kwasów nukleinowych do kodowania abcd1 w leczeniu adrenomieloneuropatii
JP6930052B2 (ja) * 2016-01-15 2021-09-01 サンガモ セラピューティクス， インコーポレイテッド 神経性疾患の処置のための方法および組成物
CA3012195A1 (en) * 2016-02-03 2017-08-10 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
CN108697774A (zh) * 2016-02-22 2018-10-23 北卡罗来纳大学教堂山分校 治疗mps i-相关失明的aav-idua载体
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
IL262211B2 (en) * 2016-04-15 2024-01-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7220080B2 (ja) 2016-05-18 2023-02-09 ボイジャー セラピューティクス インコーポレイテッド ハンチントン病治療組成物及び方法
RU2758488C2 (ru) 2016-05-18 2021-10-28 Вояджер Терапьютикс, Инк. Модулирующие полинуклеотиды
WO2018035503A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
EP3506817A4 (en) 2016-08-30 2020-07-22 The Regents of The University of California METHOD FOR BIOMEDICAL TARGETING AND RELEASE, AND DEVICES AND SYSTEMS FOR IMPLEMENTING THEM
US11111271B2 (en) 2016-09-28 2021-09-07 Cohbar, Inc. Therapeutic peptides
WO2018144441A1 (en) * 2017-01-31 2018-08-09 Regenxbio Inc. Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
US11117930B2 (en) 2017-02-23 2021-09-14 Adrx, Inc. Peptide inhibitors of transcription factor aggregation
SG11201909203WA (en) 2017-04-03 2019-11-28 Encoded Therapeutics Inc Tissue selective transgene expression
BR112019021569A2 (pt) * 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018204803A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
EP3634978A1 (en) 2017-06-07 2020-04-15 Adrx, Inc. Tau aggregation inhibitors
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
US11890329B2 (en) 2017-07-06 2024-02-06 The Trustees Of The University Of Pennsylvania AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
EP3662060A2 (en) 2017-08-03 2020-06-10 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
KR20200104852A (ko) 2017-09-22 2020-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
US11993790B2 (en) 2017-10-03 2024-05-28 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN111465691A (zh) 2017-10-03 2020-07-28 普利维尔治疗公司 用于溶酶体障碍的基因疗法
US11802294B2 (en) 2017-10-03 2023-10-31 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
EP4124658A3 (en) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
MA50942A (fr) 2017-12-01 2020-10-07 Encoded Therapeutics Inc Protéines de liaison à l'adn modifiées
EP3733855A4 (en) 2017-12-29 2021-03-03 Helixmith Co., Ltd ADENO-ASSOCIATED VIRUS (AAV) VECTOR INCLUDING A HYBRID HGF GENE INTRODUCED INTO ITS BREAST
AU2019272848A1 (en) * 2018-05-22 2020-12-03 The Brigham And Women's Hospital, Inc. Gene therapy for alzheimer's disease
WO2020068990A1 (en) 2018-09-26 2020-04-02 California Institute Of Technology Adeno-associated virus compositions for targeted gene therapy
EP3917944A1 (en) 2019-01-28 2021-12-08 Cohbar Inc. Therapeutic peptides
AU2020272974A1 (en) * 2019-04-10 2021-11-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
EP3952923A4 (en) * 2019-04-10 2023-10-18 Prevail Therapeutics, Inc. GENE THERAPIES FOR LYSOSOMAL DISEASES
US11999974B2 (en) 2019-04-10 2024-06-04 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CA3136117A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
JP2023505851A (ja) 2019-12-10 2023-02-13 武田薬品工業株式会社 ハンター病治療用のアデノ随伴ウイルスベクター
WO2021180118A1 (en) * 2020-03-11 2021-09-16 Shanghai Belief-Delivery Biomed Co., Ltd. Novel use of aspirin compound in increasing nucleic acid expression
US20230414659A1 (en) * 2020-10-30 2023-12-28 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
AU2022214429A1 (en) 2021-02-01 2023-09-14 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2022170082A1 (en) * 2021-02-05 2022-08-11 Regents Of The University Of Minnesota Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US200901A (en) * 1878-03-05 Improvement in machines for compressing and purifying air
JPS5929648A (ja) * 1982-08-10 1984-02-16 Mitsubishi Chem Ind Ltd ペプチド類
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6407061B1 (en) 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
DE69433592T2 (de) 1993-11-09 2005-02-10 Targeted Genetics Corp., Seattle Die erzielung hoher titer des rekombinanten aav-vektors
ES2220923T3 (es) 1993-11-09 2004-12-16 Medical College Of Ohio Lineas celulares estables capaces de expresar el gen de replicacion del virus adeno-asociado.
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5656785A (en) 1995-08-07 1997-08-12 The Charles Stark Draper Laboratory, Inc. Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor
US6190659B1 (en) 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
AU5445998A (en) 1996-11-19 1998-06-10 Surgx Corporation A transient voltage protection device and method of making same
AU741605B2 (en) 1996-12-18 2001-12-06 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
CA2297490A1 (en) * 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
EP1658857A1 (en) * 1997-10-29 2006-05-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
ES2324540T3 (es) 1998-05-27 2009-08-10 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.
JP2002531489A (ja) 1998-12-09 2002-09-24 カイロン コーポレイション 中枢神経系への神経栄養剤の投与
WO2000033814A2 (en) 1998-12-09 2000-06-15 Chiron Corporation Method for administering agents to the central nervous system
US7273618B2 (en) 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
US20050032841A1 (en) * 1999-04-20 2005-02-10 Steven Walkley Therapeutic compositions and methods of treating glycolipid storage related disorders
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
AU1775901A (en) * 1999-11-17 2001-05-30 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
AU783208B2 (en) 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
DK3108895T3 (en) * 2000-07-18 2018-11-26 Univ Duke Treatment of glycogen storage disease type II
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
WO2002032449A2 (en) 2000-10-13 2002-04-25 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
WO2002086105A1 (en) 2001-04-20 2002-10-31 Chiron Corporation Delivery of polynucleotide agents to the central nervous sysstem
US20030229025A1 (en) 2002-02-25 2003-12-11 Chiron Corporation Intranasal administration of MC4-R agonists
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
AU2003302724A1 (en) * 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
CN1703227A (zh) * 2002-09-27 2005-11-30 儿童医疗中心有限公司 治疗神经疾病的方法和组合物
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US7776312B2 (en) 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US20060188496A1 (en) 2005-02-23 2006-08-24 Hanne Bentz Intranasal administration of active agents to the central nervous system
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
PL1986661T3 (pl) * 2006-02-08 2019-02-28 Genzyme Corporation Terapia genowa choroby Niemanna-Picka typu A
US20100221235A1 (en) * 2006-02-08 2010-09-02 Diatos Compositions and Methods for Treating Lysosomal Storage Diseases
EP3459441A1 (en) * 2006-02-09 2019-03-27 Genzyme Corporation Slow intraventricular delivery
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
WO2008103993A2 (en) * 2007-02-23 2008-08-28 University Of Florida Research Foundation, Inc. Compositions and methods for treating glycogen storage diseases
ES2905616T3 (es) * 2007-06-06 2022-04-11 Genzyme Corp Terapia génica para enfermedades de almacenamiento lisosómico
CA2687505C (en) 2007-06-08 2013-10-08 Healthpartners Research Foundation Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
US8283160B2 (en) 2007-09-11 2012-10-09 Frey Ii William H Methods, pharmaceutical compositions and articles of manufacture for administering therapeutic cells to the animal central nervous system
EP2058401A1 (en) * 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
WO2009075815A1 (en) * 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009120978A2 (en) * 2008-03-27 2009-10-01 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor
US9415121B2 (en) * 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US11219696B2 (en) * 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
WO2010071832A1 (en) * 2008-12-19 2010-06-24 Nationwide Children's Hospital Delivery of polynucleotides across the blood brain barrier using recombinant aav9
US7989502B2 (en) 2009-02-06 2011-08-02 Sri International Intranasal delivery of modafinil
EP2396343B1 (en) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
US20110070241A1 (en) * 2009-06-30 2011-03-24 Duke University Methods for modulating immune responses to aav gene therapy vectors
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
EP2561073B1 (en) * 2010-04-23 2016-08-24 University of Massachusetts Cns targeting aav vectors and methods of use thereof
EP2394667A1 (en) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
MX2013000320A (es) * 2010-06-25 2013-06-05 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
EP3964230A1 (en) * 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
NZ702808A (en) * 2010-06-25 2016-08-26 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
PT3626257T (pt) * 2010-06-25 2021-11-12 Shire Human Genetic Therapies Métodos e composições de arilsulfatase a para a administração no snc
RU2626514C2 (ru) * 2010-06-25 2017-07-28 Шир Хьюман Дженетик Терапис, Инк. Доставка к цнс лечебных агентов
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP4234571A3 (en) * 2011-02-10 2023-09-27 The University of North Carolina at Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
DK2691529T3 (da) 2011-03-31 2019-09-23 Univ Iowa Res Found AAV2-partikel omfattende et AAV2-kapsidprotein og en vektor omfattende en nukleinsyre, der koder for en tripeptidylpeptidase 1 (TPP1) til anvendelse til behandling af sen infantil ceroid lipofuscinose (LINCL) hos et ikke-gnaver pattedyr ved intraventrikulær injektion eller ICV-indgivelse
US10196636B2 (en) * 2011-04-21 2019-02-05 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
EP2699673B1 (en) * 2011-04-21 2018-09-19 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
US8609088B2 (en) * 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
EP2709670A4 (en) * 2011-05-18 2015-01-21 Childrens Hosp Medical Center TARGETED ADMINISTRATION OF PROTEINS ACROSS THE HEMATO-ENCEPHALIC BARRIER
US20130039888A1 (en) * 2011-06-08 2013-02-14 Nationwide Children's Hospital Inc. Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
EP3290055B1 (en) * 2011-07-25 2024-08-28 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
KR20140108519A (ko) * 2011-10-12 2014-09-11 시나게바 바이오파르마, 코포레이션 재조합 인간 naglu 단백질 및 이의 용도
US9821149B2 (en) 2011-10-14 2017-11-21 Healthpartners Research & Education Methods for using ultrasound for enhancing efficiency and targeting of intranasal administration of therapeutic compounds to the central nervous system
EP4338797A3 (en) * 2011-12-02 2024-06-12 Armagen, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
KR102063195B1 (ko) * 2012-02-07 2020-01-07 글로벌 바이오 테라퓨틱스, 인크. 핵산 전달의 구획화된 방법 및 이의 조성물 및 용도
EP3818991A3 (en) * 2012-06-19 2021-07-14 University of Florida Research Foundation, Inc. Compositions and methods for treating diseases
US20150182637A1 (en) * 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
DK2879719T3 (en) * 2012-08-01 2018-09-03 Nationwide Childrens Hospital INTRATEKAL ADMINISTRATION OF RECOMBINANT ADENOASSOCATED VIRUSES
US12024568B2 (en) * 2012-09-13 2024-07-02 Cornell University Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
PL3115372T3 (pl) * 2012-11-27 2019-09-30 Biomarin Pharmaceutical Inc. Ukierunkowane terapeutyczne fuzyjne białka enzymu lizosomalnego i ich zastosowania
CA2909807C (en) * 2013-04-20 2023-08-08 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
SG11201509419QA (en) * 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
EP3024497B1 (en) * 2013-07-26 2021-01-13 University of Iowa Research Foundation Methods and compositions for treating brain diseases
ES2799437T3 (es) * 2013-08-27 2020-12-17 The Res Institute At Nationwide Childrens Hospital Productos y métodos para el tratamiento de la esclerosis lateral amiotrófica
US20160243260A1 (en) * 2013-10-24 2016-08-25 Uniqure Ip B.V. Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins
EP3909602A1 (en) * 2014-04-25 2021-11-17 University of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
HUE054768T2 (hu) * 2014-05-02 2021-09-28 Genzyme Corp AAV vektorok retina és CNS génterápiára
WO2016187017A1 (en) * 2015-05-15 2016-11-24 Mcivor R Scott Adeno-associated for therapeutic delivery to central nervous system
EP3328399B1 (en) * 2015-07-31 2023-12-27 Regents of the University of Minnesota Modified cells and methods of therapy
WO2018060097A1 (en) * 2016-09-30 2018-04-05 Laboratorios Del Dr. Esteve, S. A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
US20190269799A1 (en) * 2016-11-15 2019-09-05 Kanut LAOHARAWEE Method for improving neurological function in mpsi and mpsii and other neurological disorders
AU2018210853B2 (en) * 2017-01-17 2023-09-28 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders
AU2022258447A1 (en) * 2021-04-13 2023-10-12 Capsida, Inc. Aav compositions having high expression levels in brain

Also Published As

Publication number Publication date
KR20240093939A (ko) 2024-06-24
SG10201710448SA (en) 2018-01-30
US9827295B2 (en) 2017-11-28
RU2692251C2 (ru) 2019-06-24
US20180271956A1 (en) 2018-09-27
JP2020073559A (ja) 2020-05-14
CA2912678A1 (en) 2014-11-20
CN115120745A (zh) 2022-09-30
WO2014186579A1 (en) 2014-11-20
AU2014265417B2 (en) 2018-07-26
MX2015015560A (es) 2016-06-17
US20210085760A1 (en) 2021-03-25
US20210346473A1 (en) 2021-11-11
HK1222767A1 (zh) 2017-07-14
JP2023089201A (ja) 2023-06-27
JP2016523835A (ja) 2016-08-12
US20180264090A1 (en) 2018-09-20
BR112015028605A8 (pt) 2019-12-24
CA2912678C (en) 2023-10-10
EP2996475A1 (en) 2016-03-23
US20180036388A1 (en) 2018-02-08
US20180271955A1 (en) 2018-09-27
AU2018253615A1 (en) 2018-11-22
AU2014265417A1 (en) 2015-12-03
US20180099030A1 (en) 2018-04-12
JP2022065134A (ja) 2022-04-26
CN105377039A (zh) 2016-03-02
HK1222093A1 (zh) 2017-06-23
US20180271957A1 (en) 2018-09-27
EP2996475A4 (en) 2017-01-11
EP3622821A1 (en) 2020-03-18
CN115120746A (zh) 2022-09-30
US20210085759A1 (en) 2021-03-25
US20160120960A1 (en) 2016-05-05
KR20220119187A (ko) 2022-08-26
RU2015152546A (ru) 2017-06-20
SG11201509419QA (en) 2015-12-30
CA3209821A1 (en) 2014-11-20
MX2021009634A (es) 2021-09-08
KR20160010526A (ko) 2016-01-27
AU2021200982A1 (en) 2021-03-11
US20190298812A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
BR112015028605A2 (pt) método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central
BR112017024519A2 (pt) ?métodos para melhorar a neurocognição, para prevenir ou inibir a disfunção neurocognitiva e para proporcionar uma correção cruzada?
BR112015022472A2 (pt) método e sistema para prever a resposta a tratamentos para transtornos mentais
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112018004620A2 (pt) moduladores da expressão de kras
CR20140107A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
BR112015022417A2 (pt) métodos e composições para inibição de proteínas contendo bromodomínio
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX2020001258A (es) Moduladores del factor del complemento b.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
BR112017024243A2 (pt) Sal de (s)-csa de s-cetamina, sal de (r)-csa de s- cetamina e processos para a preparação de s- cetamina
GT201300209A (es) Compuestos y composiciones como inhibidores de la trk
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
EP4371612A3 (en) Nutritional product
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
BR112017011642A2 (pt) composto, sal farmaceuticamente aceitável, e, método para tratamento de uma doença ou condição que se beneficia de um aumento em nad+.
EA201690880A1 (ru) Тетрациклические ингибиторы аутотаксина
WO2014126965A3 (en) Compositions and methods for treating pathological calcification and ossification
BR112016002105A2 (pt) Microrganismo modificado, método para produzir alanina e uso de um microrganismo modificado
BR112017021194A2 (pt) compostos espirocíclicos
BR112016019007A2 (pt) locais genéticos associados a fertilidade acrescida em milho
BR112016001539A8 (pt) formulações em pó aperfeiçoadas de ácidos orgânicos ou ésteres tendo um sistema de anel aromático
BR112015025722A8 (pt) método, sistema e um ou mais meios de armazenamentos transitórios legíveis por computador
BR112016018162A2 (pt) microrganismo modificado, método para produzir um composto orgânico e uso de um microrganismo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 63/00 , C12N 15/00 , C12N 15/86

Ipc: A61K 31/7088 (2006.01), C12N 15/00 (2006.01), C12N

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023015866-0 PROTOCOLO 870230069673 EM 07/08/2023 17:23.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements